RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions.
Phagenesis
Phagenesis is a leading medical technology company pioneering neuromodulation therapy for neurogenic dysphagia, a swallowing disorder commonly seen after stroke or other neurological injury. The company’s Phagenyx® Neuromodulation System delivers pharyngeal electrical stimulation (PES) to retrain neural pathways and restore swallowing control. Supported by more than 30 clinical publications and real-world evidence, Phagenyx has demonstrated faster return to oral nutrition, reduced aspiration risk and shorter hospital stays. In the United States, Phagenyx is indicated for treating severe dysphagia post-stroke, while outside the U.S., it is CE-marked for use in a broad range of neurological causes.
Patronus Neurology, LLC
Patronus provides elite 24 x 7 comprehensive emergency teleneurology solutions to hospitals and stroke centers for any neurological question or emergency. Our response times put patients in contact with vascular neurologists in under two minutes.
NeuroDawn Pharmaceutical Co., Ltd.
NeuroDawn Pharmaceutical is a leading, innovation-driven biotech company specializing in the discovery and development of novel therapies for central nervous system (CNS) diseases, especially stroke.
NEAR Brain
We develop non-invasive software that accurately predicts cerebral blood flow from medical imaging, enabling neurosurgeons and neurologists to anticipate complications, improve prognosis prediction, and optimize treatment planning.
DiaMedica Therapeutics, Inc.
DiaMedica Therapeutics is a clinical-stage biopharma company developing DM199, a recombinant form of KLK1, to improve outcomes in ischemic stroke. DM199 is being evaluated in the Phase 2/3 ReMEDy2 clinical trial.
Chiesi
Chiesi USA is the U.S. affiliate of Chiesi Farmaceutici, S.p.A, a specialty pharmaceutical company committed to the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings.
Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in lung fibrosis and stroke. With origins as a spin-out from the University of Oxford, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans associated with Interstitial Lung Disease (ILD). Results from REVISE PPF, a multicenter study presented at CHEST and ERS, showed e-Lung could have supported an earlier diagnosis of PPF in 71% of patients and up to 28 months earlier. | Brainomix is an Oxford-based company specializing in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions in stroke, lung fibrosis and cancer.
Aidoc Medical Ltd.
Powered by the proprietary aiOS™, Aidoc’s clinical AI solutions aggregate medical data enabling clinicians to operationalize the unexpected and work with a continued focus on the patient.